The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Subscribe To Our Newsletter & Stay Updated
